Phoenix Life Sciences International Is Now Accepting Bids for Hemp CBD Producers and Manufacturers

 DENVER, CO – December 12, 2018 – Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it is now accepting bids from U.S. licensed producers of industrial hemp to supply various products to be used in the formulation of its botanical pharmaceuticals.

“As we move forward with our mission of transforming the future of global healthcare, our next step is partnering with a GMP licensed hemp producers in the U.S. that shares our values and mission to push botanical pharmaceuticals forward throughout the world,” said Phoenix Life CEO Martin Tindall. “While we build out our production capacity, we are proud to join other well-respected companies in the space and begin producing our products on a larger scale.”

Phoenix Life is seeking a Good Manufacturing Practice (GMP) licensed industrial hemp partner for both U.S. and foreign markets to commence in January 2019. Products requested by Phoenix Life include soft gel capsules, atomizer inhalers and wholesale cannabidiol (CBD) oil. All suppliers must utilize biomass that has been produced under organic conditions, and preference will be on USDA organic certification. The company also encourages new and innovative manufacturers to apply for the partnership.

Producers bidding to partner with Phoenix Life must have a minimum production capacity of 24,000 bottles of 120 soft gels per bottle per month (2.8mil soft gels per month) and 1,000 atomized inhalers per month. These capacity requirements are expected to increase in the U.S. market in 2020.

Phoenix Life aims to partner with the single-payer healthcare systems of both established and emerging economies to conduct medical studies on cannabis for diabetes and establish programs for diabetes patients to receive the company’s botanical products. Through these partnerships, Phoenix Life hopes to recruit the best minds in the pharmaceutical space to join its mission.

Interested parties should please contact with full contact details and information on which products the company would like to submit.

To learn more about Phoenix Life Sciences International, please visit

About Phoenix Life Sciences International Limited

Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.


Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.


These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S.


Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.

Investor Contact:

Phone: 1.888.717.5655 or international +1.720.699.7222


Media Contact:

Kathryn Reinhardt

CMW Media


Leave a Reply

Sign up for our newsletter

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact